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NHThe subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or
following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular
systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the
diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of pa-
tients undergoing treatmentwith anthracyclines and/or human epidermal growth factor receptor (HER) 2-positive targeted
treatment (e.g., trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing
echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society out-
lines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines
and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques
are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are
also presented. (J Am Coll Cardiol CardioOnc 2021;3:1–16) © 2021 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)N 2666-0873 https://doi.org/10.1016/j.jaccao.2021.01.011
m the aCardio-Oncology Service, Liverpool Heart and Chest NHS Foundation Trust, Liverpool, United Kingdom; bCardio-
cology Service, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom; cCardio-Oncology Service, Hatter Car-
vascular Research Institute, University College London and University College London Hospitals NHS Foundation Trust,
ndon, United Kingdom; dPerelman School of Medicine at the University of Pennsylvania, Philadelphia, USA; eBaker Heart and
betes Institute, Melbourne, Australia; fUniversity Hospital South Manchester NHS Foundation Trust, Manchester, United
gdom; gEast Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom; hUniversity Hospitals Birmingham
S Foundation Trust, Birmingham, United Kingdom; iNorth West Anglia Foundation Trust, United Kingdom; jLiverpool John
ores University, Liverpool, United Kingdom; kUniversity Hospitals of Leicester NHS Trust, Leicester, United Kingdom; lRoyal
rsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; mImperial College Healthcare NHS
st, London, United Kingdom; nThe Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom; oWest Suffolk
S Foundation Trust, Bury St. Edmunds, United Kingdom; pRoyal Brompton and Harefield NHS Foundation Trust and Imperial
llege London, London, United Kingdom; qThe Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United
gdom; rBelfast Health and Social Care Trust, Belfast, United Kingdom; sRoyal Liverpool and Broadgreen University Hospitals
S Trust, Liverpool, United Kingdom; and the tDepartment of Cardiology, Royal United Hospitals Bath NHS Foundation Trust,




A2C = apical 2-chamber
A3C = apical 3-chamber
A4C = apical 4-chamber
BSE = British Society of
Echocardiography
CMR = cardiac magnetic
resonance
CTRCD = cancer therapy–
related cardiac dysfunction
ECG = electrocardiogram
GLS = global longitudinal
strain
HER2 = human epidermal
growth factor receptor 2
LV = left ventricular
LVEF = left ventricular ejection
fraction
MV = mitral valve
RH = right heart
ROI = region of interest
RV = right ventricular
TDI = tissue Doppler imaging
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HIGHLIGHTS
 Cardio-oncology patients account for an
increasing proportion of echocardiogra-
phy requests.
 Accurate assessment of LV systolic
function is critical to decision-making in
this patient group.
 2D LVEF, 3D LVEF, GLS, and RV assess-
ment should be used in the echocardio-
graphic assessment of these patients.
 The clinical implications of a significant
decline in GLS with potentially car-
diotoxic cancer therapy require further
investigation.A dvances in cancer detection andtreatment have resulted in agrowing number of cancer survivors.
Cardio-oncology is a relatively new subspe-
cialty that aims to prevent, detect, monitor
and treat the cardiac complications of cancer
therapy (1). The goal of the cardio-oncologist
is to provide optimal cardiovascular care for
patients with cancer in a multidisciplinary
setting involving oncologists, cardiologists,
surgeons, cardiac physiologists/scientists,
specialist nurses, pharmacists, and allied
health professionals (2). Cancer therapy–
related cardiac dysfunction (CTRCD) is a
frequently encountered clinical presenta-
tion, and transthoracic echocardiography is
the cornerstone of its screening and
detection.
The British Society of Echocardiography
(BSE) has recently published an updated
minimum dataset for a standard adult
transthoracic echocardiogram (3)
(Supplemental Appendix). This cardio-
oncology guideline is designed to be used
in conjunction with the minimum dataset
and provides guidance on transthoracic
echocardiographic image acquisition and
data interpretation in patients undergoing
treatment with anthracyclines and/or
trastuzumab.This consensus guideline:
1. Defines the standard echocardiography protocol
for the assessment of left ventricular (LV) function
in those undergoing anthracyclines and/or human
epidermal growth factor receptor 2 (HER2)-tar-
geted therapy.
2. Defines cardiotoxicity and specifically CTRCD
with anthracyclines and/or HER2-targeted
therapy.
3. Provides strategies to enable the acquisition of
high-quality echocardiography for patients un-
dergoing anthracyclines and/or HER2-targeted
therapy.
4. Reviews the nonechocardiographic considerations
for clinical decision-making; reviews risk factorsd Kingdom. *Drs. Dobson and Ghosh contributed equally to this w
er. Juan Carlos Plana Gomez, MD, served as the Guest Associate
s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
thor Center.
received June 12, 2020; revised manuscript received January 18for cardiotoxicity; and provides guidance for
referral to a cardio-oncology service.
BACKGROUND
Anthracyclines (e.g., doxorubicin, epirubicin, dauno-
rubicin, and idarubicin) and the monoclonal antibody
trastuzumab (Herceptin, Genentech, South San Fran-
cisco, California) are commonly implicated in the
development of LV dysfunction (4). Although there are
other cardiotoxic anticancer therapies, in our experi-
ence, patients receiving anthracyclines and/or trastu-
zumab account for the majority of cardio-oncology
echocardiograms performed, hence are the focus
of this guideline. Trastuzumab may also be prescribed
in combination with pertuzumab, another HER2-pos-
itive–targeted monoclonal antibody, or with emtan-
sine (Kadcyla/T-DM1, Genentech), which may be
associatedwith additional cardiovascular concerns (5).
Many mechanisms are postulated to explain
anthracycline-induced cardiotoxicity. Generation of
excess reactive oxygen species and oxygen free rad-
icals causing damage to deoxyribonucleic acid (DNA),
ribonucleic acid (RNA), proteins, and membrane
lipids, and resultant cardiomyocyte death is one of
the most commonly accepted cardiotoxicity mecha-
nisms (6). The mechanisms responsible for
trastuzumab-related cardiotoxicity are less clear butork. Anju Nohria, MD, served as the Editor-in-Chief
Editor for this paper.
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
, 2021, accepted January 19, 2021.
TABLE 1 Minimum Requirements for Baseline Assessment for Patients Receiving Anthracyclines/Trastuzumab (in Addition to the Full BSE Minimum Dataset in the
Supplemental Appendix)
View (Modality) Measurement Explanatory Note Image
Vital signs Blood pressure, heart rate and rhythm
Apical 3D 3D volumes and LVEF ECG signal with clear R-wave.
Adjust scanner settings to ensure optimal resolution.
Ensure ROI is within the 3D volume sector. Maximize the frame rate,
adjusting number of subvolumes according to patient breath-holding
capability as needed.
Acquire images with the probe maintained in a steady position and at end-
expiration.
Before accepting acquisition, review volume and 9-slice view to ensure no
stitch artifacts.
A4C/A3C/A2C GLS GLS measurement Optimal ECG signal with minimal heart rate variability should be present
across 3 cardiac cycles.
Heart rate variability will limit the calculation of GLS values, which can be
problematic in patients with atrial fibrillation. High-quality image
acquisition, maintaining a frame rate of 40 to 90 frames/s at a normal
heart rate, is key.
Clear endocardial and epicardial definition is required to ensure adequate
segmental tracking throughout the cardiac cycle. Markers are placed
in each of the respective basal and apical regions, using automated
tracking where possible to maintain reproducible results. Automated
tracking should also be combined with a visual assessment of tracking
in each view across the whole ROI, including the endocardial and
epicardial border. If more than 2 segments in any 1 view are not
adequately tracked, the calculation of GLS should be avoided.
3D ¼ 3-dimensional; A2C ¼ apical 2 chamber; A3C¼ apical 3 chamber; A4C ¼ apical 4 chamber; BSE¼ British Society of Echocardiography; ECG ¼ electrocardiogram; GLS ¼ global longitudinal strain; LVEF¼
left ventricular ejection fraction; ROI ¼ region of interest.
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likely are related to inhibition of the neuregulin-1
(NRG-1)/ErbB signaling pathway (7). Commonly, but
not in all cases, there is recovery of LV function with
trastuzumab cardiotoxicity (8).
The addition of trastuzumab to anthracycline
chemotherapy alone improves the overall survival of
patients with HER2-positive tumors by approximately
33%, with a 50% reduction in disease recurrence
(9,10). For this reason, the management of cardiac
dysfunction should first consider the initiation of
cardioprotective therapies, rather than withholding
prognostically important oncology treatment. Man-
agement decisions require close collaboration be-
tween oncology and cardiology specialists. In
addition, the risk of cardiotoxicity is not just an issueduring oncology treatment (chemotherapy and/or
radiotherapy) but can remain a concern for many
years thereafter (11,12).
THE ROLE OF ECHOCARDIOGRAPHY AND THE
RECOMMENDED CARDIO-ONCOLOGY PROTOCOL
All patients should undergo a comprehensive base-
line echocardiogram to include the BSE minimum
transthoracic dataset (Supplemental Appendix) with
additional cardio-oncology measurements (Table 1).
Best practice for the minimum dataset for a targeted
cardio-oncology protocol includes 2-dimensional (2D)
and 3-dimensional (3D) volumes, LV ejection fraction
(LVEF), global longitudinal strain (GLS), right
TABLE 2 Cardio-Oncology Targeted Echocardiogram Reporting Protocol
View (Modality) Measurement Explanatory Note Image







Trace the endocardial border. Depending on the vendor, the MV level contour is
made by a straight line at the beginning or end of tracing. LV length is defined as
the distance between the midpoint of the MV-level line and the most distal point
of the LV apex. Take care to ensure the LV is not foreshortened. Papillary muscles
and trabeculations are included in the volumes and considered part of the
chamber.
Measure at end-diastole and end-systole.
Volumes indexed to BSA.
Apical 3D 3D volumes and
LVEF
See Table 1
A4C/A3C/A2C GLS See Table 1
A4C LV TDI S0 Place sample volume (5 to 10 mm) at or within 1 cm of the insertion of the MV
leaflets.
Angle of interrogation should be as parallel to Doppler beam as possible.
Measure at end-expiration.
Optimize scale and sweep speed (100 mm/s).
Average both septum and lateral wall measurement.





RVD1: Basal RV diameter. Measured at the maximal transverse diameter in the basal
one-third of the RV.
RVD2: Mid-RV diameter measured at the level of the LV papillary muscles.
RVD3: RV length, from the plane of the tricuspid annulus to the RV apex.
CWD TV TR peak velocity
(TRVmax)
Peak TR velocity is measured by CWD across the tricuspid valve. Ensure the CWD to
flow angle is correctly aligned. Eccentric jets can lead to incomplete Doppler
envelopes and underestimation of TR velocity. A high sweep speed (100 mm/s)
can help to differentiate between true velocities and artifact. Measure from a
complete TR envelope. Choose the highest velocity. Accuracy is greatest when
ultrasound and blood flow are parallel.
A4C RV (TDI) RV S0 PW tissue Doppler S0 wave measurement taken at the lateral tricuspid annulus in
systole. It is important to ensure the basal RV free wall segment and the lateral
tricuspid annulus are aligned with the Doppler cursor to avoid velocity
underestimation.
A disadvantage of this measure is that it assumes that the function of a single
segment represents the function of the entire ventricle, which is not likely in
conditions that include regionality such as RV infarction.
Normal value $9 cm/s (27).
Continued on the next page
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TABLE 2 Continued





TAPSE This is an angle-dependent measurement, and therefore, it is important to align the
M-Mode cursor along the direction of the lateral tricuspid or mitral annulus.
Select a fast sweep speed.
Measure total excursion of the tricuspid annulus.
Normal value $17 mm (60).
2D ¼ 2 dimensional; BSA¼ body surface area; CWD ¼ continuous-wave Doppler; LA ¼ left atrium; LV ¼ left ventricle; MM ¼M-mode; MV ¼mitral valve; PW ¼ pulsed wave; RV ¼ right ventricle; RVD ¼ right
ventricular diameter; TAPSE ¼ tricuspid annular plane systolic excursion; TDI ¼ tissue Doppler imaging; TR ¼ tricuspid regurgitation; TV ¼ tricuspid valve; other abbreviations as in Table 1.
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ventricular (RV) size and systolic function assess-
ment, tricuspid regurgitant velocity (TRV), and blood
pressure measurement (Table 2). Measurement tech-
niques are described in Tables 1 and 2, and the overall
clinical approach to echocardiographic monitoring is
described in the Central Illustration.
BASELINE AND SERIAL ECHOCARDIOGRAPHIC
ASSESSMENT. The role of transthoracic echocardi-
ography screening in the cardio-oncology setting is to
assess cardiac function at baseline and to diagnose
CTRCD at the earliest possible stage (Central
Illustration). This enables informed decisions
regarding timely commencement of cardioprotective
medications and the safe continuation of cardiotoxic
cancer therapy. It is crucial that accurate and repro-
ducible parameters of LV systolic function are used so
that a detected decline in LV systolic function truly
reflects toxicity (13).
Baseline risk stratification of cardiotoxicity must
take into consideration both the proposed cancer
therapy and individual patient-related factors
(Table 3). A more personalized tailored approach to
surveillance is recommended in increased-risk pa-
tients compared with low-risk patients (Central
Illustration). Recent Heart Failure Association–
International Cardio-oncology Society expert posi-
tion statements add to the published reports
regarding the frequency of surveillance echocardio-
grams in patients stratified to low, medium, or high
risk who then receive anthracyclines or trastuzumab
(Table 4) (14,15). In patients with normal LV systolic
function at baseline, subsequent echocardiograms in
asymptomatic patients should be targeted studies
(Table 2). However, any patient with new cardiovas-
cular symptoms while receiving cancer therapy
should undergo a full echocardiogram (16).
The optimum frequency of echocardiograms dur-
ing and after cancer therapy is unclear especially inthe context of current pandemics (e.g., COVID-19)
(17,18). Recommendations for echocardiography dur-
ing and after anthracycline-containing chemotherapy
also differ, with the majority of guidelines not quan-
tifying frequency of monitoring (19,20). There is wide
variation in guideline recommendations (19) on the
frequency of echocardiographic monitoring for pa-
tients receiving trastuzumab, ranging from every
3 months (21) to an undefined “periodically” (10)
(Table 4). Furthermore, there is no strong evidence to
support a specific schedule of screening or any evi-
dence that it improves outcomes for screened pa-
tients (22). However, screening every 3 months is still
recommended by the U.S. Food and Drug Adminis-
tration, although the frequency is admittedly
controversial, and compliance is limited (23).
Historically, trastuzumab has been temporarily
held or even discontinued in patients who develop LV
systolic dysfunction. However, there are increasing
data to suggest that patients with asymptomatic re-
ductions in LVEF to 40% to 49%, with guidance from
a cardio-oncology team and personalized monitoring
and treatment, can safely complete their cancer
treatment without a significant increase in cardiac
events (24,25). We therefore recommend a personal-
ized approach to patient surveillance, as emphasized
in a position statement from the Heart Failure
Association–European Association of Cardiovascular
Imaging (15).
Echocardiography 3 to 12 months post-cardiotoxic
treatment is recommended in all patients, with the
optimum timing dependent upon the individual pa-
tient’s risk (16). Appropriate frequency of repeat
echocardiography thereafter remains to be fully
defined and depends upon whether any cardiotox-
icity occurred during the treatment phase (15), with
international recommendations varying from 1- to
5-year intervals (16,26). Decisions regarding long-
CENTRAL ILLUSTRATION Echocardiography Protocol in Patients Undergoing Treatment With
Anthracyclines/HER2-Positive–Targeted Therapy
Dobson, R. et al. J Am Coll Cardiol CardioOnc. 2021;3(1):1–16.
Assessment at baseline, during therapy (including patients on indefinite HER2-positive–targeted therapy in case of metastatic disease) and
long-term follow-up after the completion of cancer therapy. BSE ¼ British Society of Echocardiography; GLS ¼ global longitudinal strain;
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction.
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TABLE 3 Identification of the Patient at Increased Risk of Cardiotoxicity
Lower Risk Increased Risk
Therapy-related risk factors
Lower lifetime dose of anthracycline
<Doxorubicin 250 mg/m2 or equivalent
No previous anthracycline/trastuzumab-related cardiotoxicity
Absence of sequential anthracycline and trastuzumab therapy
Low-dose radiation therapy to central chest including heart in radiation field <30 Gy
Increased lifetime dose of anthracycline
>Doxorubicin 250 mg/m2 or equivalent—high risk
>400 mg/m2 or equivalent—very high risk
Prior anthracycline/trastuzumab-related cardiotoxicity
Sequential anthracycline and trastuzumab therapy









Absence of pre-existing cardiovascular disease (e.g., CAD, PAD, cardiomyopathy,
severe valvular heart disease, heart failure, or diabetes)
Normal kidney function or chronic kidney disease stage 1
Biomarkers:
Normal baseline troponin and/or NT-proBNP
Normal cardiac troponin or NT-proBNP during cancer therapy
Female
Age 50 to 64 yrs—high risk and $65 yrs—highest risk
Presence of traditional cardiovascular risk factors: Hypertension, smoking,
obesity, dyslipidemia, insulin resistance
Past medical history:
Reduced or low-normal LVEF (50% to 54%) pre-treatment
Presence of pre-existing cardiovascular disease (e.g., CAD, PAD,
cardiomyopathy, severe valvular heart disease, heart failure, or diabetes)
Chronic kidney disease stage 2 (eGFR <78 ml/min/1.73 m2) (84)
Biomarkers:
Elevated* baseline troponin and/or NT-proBNP
Elevated* cardiac troponin or NT-proBNP during cancer therapy
*Elevated above the upper limit of normal for local laboratory reference range.
CAD ¼ coronary artery disease; eGFR ¼ estimated glomerular filtration rate; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PAD ¼ peripheral arterial
disease.
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term surveillance should take into consideration a
patient’s total anthracycline dose, exposure to other
potentially cardiotoxic treatments (including radio-
therapy), cardiovascular comorbidities, cardiotoxicity
during treatment, and LV systolic function during
and at the end of treatment.
ECHOCARDIOGRAPHY-BASED DEFINITIONS
OF CARDIOTOXICITY
The definition of cardiotoxicity is varied and not
limited to LV systolic dysfunction and CTRCD (19).
The definition of cardiotoxicity based solely on LVEF
also varies significantly (10,16,21). We define CTRCD
as a decrease in LVEF by >10% (10 absolute percent-
age points) to a value <50%. This is in keeping with
BSE-published normal/borderline normal ranges (27)
and European Society for Medical Oncology
consensus recommendations (26). A LVEF of 50% to
54% is considered to be borderline low and will
require more information before labelling the patient
as having normal or abnormal LV systolic function.
We recommend that, if possible, 3D LVEF is
measured due to both its reported superior repro-
ducibility compared with 2D LVEF in patients un-
dergoing anticancer therapy (28) and suggestions that
3D LVEF changes are more pronounced than and
precede 2D LVEF changes in such patients (29). 3D
LVEF has been shown to allow accurate serial quan-
tification of LV systolic function and identification of
changes in oncology patients (13). Declines in LVEF
are usually accompanied by a significant change inGLS. Therefore, if GLS is normal in the presence of a
reduced LVEF, a review of the echocardiograms to
reassess the accuracy of all measurements is recom-
mended. If there is still a significant and unexplained
discrepancy between change in LVEF and GLS, adju-
dication with cardiac magnetic resonance (CMR) im-
aging should be considered.
Normal GLS values vary with age, sex, loading
conditions, and different vendors; therefore, defini-
tion of abnormal GLS is not straightforward. It is
important that heart rate and blood pressure are
recorded because variation will need to be considered
if there are temporal changes in GLS measurements.
Much of the existing published reports on GLS values
are based on General Electric vendor-specific data,
and for the purpose of this guideline, we define a
normal GLS value as being 17% or more negative for
males and 18% or more negative for females (30–32).
A relative change in sequential GLS >15% (e.g., 22%
to 18%) is considered to be significant (33). A wors-
ening in GLS is known to predict a subsequent decline
in LVEF, with GLS-guided cardioprotective therapy
potentially reducing a decline in LVEF (34). The
change in GLS is essential in recognition of car-
diotoxicity, such that each patient acts as their own
control. For this reason, comprehensive baseline
echocardiography before cancer therapy is critical.
Reduction in GLS into the abnormal range as
described or borderline values and declines in LVEF
within the normal range should not be taken in
isolation, especially in asymptomatic patients, but
be interpreted in the overall clinical context. A
TABLE 4 Frequency of Echocardiographic Monitoring During Anthracycline or Trastuzumab (Anti-HER2) Therapy According to
Published Guidelines
Guideline, Year (Ref. #) Recommendation for Frequency of Echocardiography During Therapy
HFA-EACVI, 2020 (15)
Anthracyclines Low risk*; after cycle of cumulative dose 240 mg/m2 doxorubicin or equivalent, then every additional 100 mg/m2 or every 2 cycles
Medium risk*; following 50% of planned total treatment and after cycle of cumulative dose 240 mg/m2 doxorubicin or equivalent
High risk*; every 2 cycles, consider after every cycle above 240 mg/m2 doxorubicin or equivalent
Anti-HER2 (neoadjuvant and
adjuvant)
Low risk*; every 4 cycles (12 weeks)
Medium risk*; every 3 cycles (9 weeks), then reduce to every 4 cycles if stable at 4 months
High risk*; every 2 cycles 6 weeks), then reduce to every 3 cycles if stable at 4 months
Anti-HER2 (long term) Low risk*; every 4 cycles in year 1, every 6 cycles in year 2, then reduce to every 6 months
Medium risk*; every 3 cycles, then if stable reduce to every 6 months
High risk*; every 2 or 3 cycles for 3 months, then reduce to every 4 cycles in year 1, then reduce frequency
ESMO, 2020 (26)
Anthracyclines After a cumulative dose of 250 mg/m2 doxorubicin or equivalent, then after each additional 100 mg/m2
Anti-HER2 Every 3 months (higher-risk patients may require more frequent monitoring)
Anti-HER2 (long term) General surveillance, which may include cardiac imaging
ASCO, 2017 (16)
Anthracyclines Frequency of surveillance should be determined by health care providers. Routine surveillance imaging may be offered in patients considered
to be at increased risk of cardiac dysfunction.
Anti-HER2 Frequency of surveillance should be determined by health care providers. Routine surveillance imaging may be offered in patients considered
to be at increased risk of cardiac dysfunction.
CCS, 2016 (85)
Anthracyclines No recommendation made
Anti-HER2 Every 3 months
ESC, 2016 (10)
Anthracyclines After 200 mg/m2 of doxorubicin or equivalent
Anti-HER2 Every 4 cycles
ASE, 2014 (33)
Anthracyclines After 240 mg/m2 of doxorubicin or equivalent, then after each additional 50 mg/m2
Anti-HER2 Every 3 months
*Risk is calculated according to therapy and patient-related factors, including age, and cardiovascular risk factors. For more details, the reader is directed to the original guideline (15).
ASCO ¼ American Society of Clinical Oncology; ASE ¼ American Society of Echocardiography; CCS ¼ Canadian Cardiovascular Society; EACVI ¼ European Association of Cardiovascular Imaging;
ESC ¼ European Society of Cardiology; ESMO ¼ European Society of Medical Oncology; HER ¼ human epidermal growth factor; HFA ¼ Heart Failure Association.
Dobson et al. J A C C : C A R D I O O N C O L O G Y , V O L . 3 , N O . 1 , 2 0 2 1
Cardio-Oncology Echocardiography Protocol for Anthracyclines and/or Trastuzumab M A R C H 2 0 2 1 : 1 – 1 6
8
decline in LVEF by >10 percentage points to an ab-
solute value >50% with a lower limit of normal of
GLS is a grey area that might suggest potential sub-
clinical cardiotoxicity, although in some cases, it
may reflect normal, physiological variability (35). In
these circumstances, it is important to take other
factors (such as symptoms, other echocardiographic
parameters of LV systolic function, and biomarkers)
into consideration. GLS may have added value,
particularly in cases of borderline LVEF, with a
normal strain measurement providing some reas-
surance (36,37). Patients with normal LVEF, but
abnormally low strain, also require further investi-
gation to rule out potential causes such as cardiac
amyloidosis, infiltration or hypertensive cardiomy-
opathy (38). These echocardiograms should be
reviewed (to also ensure adequate technical quality)
in conjunction with a clinical assessment and
biomarker measurement. Certainly, there is a need
for longer-term data to define the natural history ofLVEF and GLS changes, as well as the prognostic
implications of potential subclinical cardiotoxicity.
RECOMMENDATIONS
Definition of cardiotoxicity by echocardiography:
 LVEF: A decline in LVEF by >10 absolute percent-
age points to a value <50%,
Definition of probable subclinical cardiotoxicity by
echocardiography:
 LVEF: A decline in LVEF by >10 absolute percent-
age points to a value $50% with an accompanying
fall in GLS >15% (where GLS measurement is
available).
Definition of possible subclinical cardiotoxicity by
echocardiography:
 LVEF: A decline in LVEF by <10 absolute percent-
age points to a value <50%.
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or
 LV GLS: A relative percentage reduction in GLS by
>15% from the baseline value.
The detection of cardiotoxicity or probable/
possible subclinical cardiotoxicity is achieved via
advanced echocardiographic measures (2D/3D LVEF
and GLS). For best practice, centers undertaking
surveillance of these patients should have the ability
to perform 2D/3D LVEF and GLS assessment.
LV FUNCTION ASSESSMENT BY
ECHOCARDIOGRAPHY
CARDIAC RHYTHM AND RATE. Sequential assess-
ments for those not in sinus rhythm may be prob-
lematic. In atrial fibrillation due to the persistent
variation in cardiac cycle length, measures of ven-
tricular systolic and diastolic function may have
limited reliability. When preceding and pre-preceding
RR intervals are within 60 ms of each other and both
exceed 500 ms, measures of systolic function on a
single beat are similar to those averaged over 15 cy-
cles of varying durations (39). These findings suggest
that selection of beats with similar RR intervals is
more important for reproducibility than the total
number of measurements made.
BLOOD PRESSURE. Recording of blood pressure is
essential because parameters such as LVEF, tissue
Doppler indices, and GLS are load dependent. A
substantial increment of blood pressure may be
responsible for an apparent change in function,
without necessarily indicating myocardial disease,
because poorly controlled hypertension is associated
with abnormal strain (40).
ACCURATE ASSESSMENT OF 2D LVEF. LVEF is one
of the most commonly used echocardiographic
methods to assess LV systolic function. This repre-
sents the fraction of blood within the LV that is
ejected in 1 cardiac cycle. Because it is difficult to
quantify a 3D structure using 2D imaging, the tech-
niques developed with 2D echocardiography rely on
measuring the ventricle in standard planes.
We do not support the use of qualitative “eyeball”
assessments to determine LVEF values or ranges. The
2D volumetric Simpson’s method for the assessment
of LVEF is based on the principle of slicing the LV
from the apex down to the mitral valve (MV) into a
series of discs. The volume of each disc is then
calculated using the diameter and thickness of each
slice. It is assumed that the LV is circular at each
level. Accuracy is improved by using diameters in 2
planes, separated by 60 of rotation (apical 4 and 2
chamber) so that the disc surface area is moreprecisely defined. Acquisitions should be made at
end-respiration, and the image should be adjusted
using gain, compress, and dynamic range to ensure
optimal endocardial delineation and elongation of the
entire LV length, without foreshortening. High-
quality images are critical for accurate quantifica-
tion. For more detailed guidance, the reader is
directed to the BSE minimum dataset (Supplemental
Appendix) (3). The endocardial surface should be
traced at end-diastole and end-systole to encompass
the whole of the LV. Papillary muscles and trabecu-
lations are excluded from the endocardial tracing and
are considered part of the chamber. This can be ach-
ieved either on the machine or by using an off-line
analysis software package. LVEF is calculated as the
difference between end-diastolic volume and end-
systolic volume (stroke volume) as a percentage of
the end-diastolic volume. Intraobserver and interob-
server variability has been reported as 3.3% and 4%
respectively with a minimum detectable difference of
9% to 11% (13,41). When describing 2D LVEF, the
report conclusion should always note the most recent
estimate of LVEF and include a comparison with the
baseline value.
3D LVEF. The 2D echocardiographic assessment of
LVEF has inherent limitations because it makes geo-
metric assumptions of the LV. This consideration is
especially important for serial echocardiograms
because exact plane duplication is almost impossible.
3D echocardiography, although still requiring high-
quality, reproducible images, is an advance on the
Simpson’s method because it allows contouring of the
cavity within the 3D space of the echocardiographic
volume acquisition. Therefore, there is no assump-
tion that the short-axis view of the ventricle is cir-
cular. Instead, one can contour the actual shape of the
ventricle in all dimensions. Consequently, 3D LVEF
calculation has a smaller detected % change of
approximately 5% to 8% and, because it is semi-
automated, has better intra- and interobserver vari-
ability (13). There is superior temporal variation of 3D
LVEF compared with 2D LVEF over a 12-month period
in stable patients receiving chemotherapy (3% vs. 5%)
(13). Commercially available scanners contain soft-
ware tools that allow the 3D assessment of LV vol-
umes and LVEF. It is to be remembered, however,
that 3D imaging remains sensitive to image quality,
and it is good practice to record and analyze both 2D
and 3D images, because deterioration of image qual-
ity during follow-up is most likely to affect 3D images.
There remains some variation in 3D LVEF calculation
between specific vendors, and we recommend that
the same machine and analysis software are used for
serial echocardiograms (42). When reporting 3D LVEF
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recent estimate of LVEF and include a comparison to
the baseline value.
Full-volume datasets allow the generation of a 3D
dataset with the final image of the heart created by
acquiring several single or several subvolumes over
the corresponding number of sequential cardiac cy-
cles. Attention to breath-hold is essential to avoid
stitching artifact. The greater the number of sub-
volumes used, the higher the frame rate and tem-
poral resolution, albeit at greater risk of stitching
artifact. Newer technology allows increased volume
rates and reduced time for complete cardiac volume
acquisition in the estimation of 3D LVEF, making it
comparable to CMR imaging (43). It should be
recognized that there is a tradeoff between temporal
and spatial resolution. Temporal resolution (i.e.,
volume or frame rate) allows localization of an
anatomic structure in a point in time. This can be
improved by reducing the sector size (width and
depth). Spatial resolution is the ability to differen-
tiate 2 points in space and is dependent on the
number of scan lines per volume (scan line density),
However, increasing scan lines lengthens the acqui-
sition time and lowers the volume rate (44).
Images should be obtained during shallow breath-
ing, preferably in end-expiration. If deep inspiration
is needed to obtain optimal image quality, this should
be documented in the echocardiogram report so that
it can be reproduced at the next visit. Finally, it is
good practice for the sonographer to quantify LVEF
on 2D and 3D images while the patient is still present.
Performing the analysis at the time also allows repeat
image acquisition in case of contouring difficulty.
How to acquire 3D echo volumes for LVEF
assessment:
 Ensure high-quality electrocardiogram (ECG) trace
with a clear R-wave. This enables appropriate 3D
full-volume triggering.
 Ensure the region of interest (ROI) is within the 3D
volume sector. Reduce the sector as needed to
focus on the ROI.
 As for 2D imaging, adjust scanner settings so that
the best 3D resolution is available.
 Adjust gain appropriately. Low gain settings result
in echo “dropout,” and excess gain reduces reso-
lution and causes a loss of the 3D perspective or
depth in the dataset.
 Optimize frame rate and adjust number of sub-
volumes according to patient breath-holding ca-
pacity as needed.
 Acquire images with the probe maintained in a
steady position and at end-expiration. Following acquisition, review the image to look for
any stitch artefact.
CONTRAST ECHOCARDIOGRAPHY/ULTRASOUND
ENHANCING AGENTS. Inadequate LV endocardial
border definition can lead to errors in LV volume and
LVEF estimation. Accurate LVEF assessment is
particularly important where values obtained fall on
boundaries that influence treatment decisions. Poor
endocardial definition can occur in patients under-
going cancer treatment (e.g., following mastectomy,
chest irradiation, or breast reconstruction surgery)
(33) or secondary to body habitus. The use of echo-
cardiographic contrast for LV chamber opacification is
now widely accepted when 2 contiguous LV segments
from any apical view are not adequately visualized on
noncontrast images (45). Tracing LV borders more
reliably leads to inclusion of LV trabeculation within
the LV cavity after contrast. As a result, LV volumes
(both in systole and diastole) are commonly greater
than those recorded with noncontrast imaging,
although LVEF is usually analogous. The minimum
detectable difference for 2D contrast LVEF has been
noted to be in the order of 4% (46), which is signifi-
cantly better than the 9% to 11% for noncontrast 2D
LVEF. However, the superior performance of LV
contrast has not been consistently proven. One study
demonstrated inferior reproducibility with contrast
echocardiograms compared with noncontrast 2D and
3D echocardiograms (13). Use of the same methodol-
ogy in sequential testing is thus recommended. It is to
be noted that the use of contrast has unpredictable
effects on 2D speckle tracking and is best done after
strain acquisition.
TISSUE DOPPLER ASSESSMENT OF SYSTOLIC AND
DIASTOLIC FUNCTION. Tissue Doppler echocardiog-
raphy has become an established component of the
diagnostic ultrasound examination, enhancing inter-
rogation of myocardial motion. Although LVEF re-
flects the sum contribution of several regions, it does
not provide information on regional function or on
the underlying myocardial mechanical activity. Con-
ventional Doppler techniques assess velocity of blood
flow by measuring high-frequency, low-amplitude
signals from small, fast-moving blood cells. Tissue
Doppler imaging (TDI) uses the same Doppler princi-
ples to quantify the higher-amplitude, lower-velocity
signals of myocardial tissue motion. TDI depicts
myocardial motion at a specific location in the heart.
High-velocity signals from the blood are filtered out
and amplification scales suitably adjusted so that
Doppler signals from tissue motion can be recorded.
Tissue velocity indicates the rate at which a particular
point in the myocardium moves toward or away from
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dent and only measures the vector of motion that is
parallel to the direction of the ultrasound beam. Mean
mitral annular S0 should be acquired at end-
expiration. For more detailed guidance, the reader is
directed to the BSE minimum dataset (Supplemental
Appendix) (3). Normal age-related values for mean
mitral annular S0 are described in recent guidance
(27). Both tissue Doppler and grey scale imaging have
been used to calculate mitral annular plane
displacement, which is a longitudinal function
parameter analogous to strain.
In breast cancer patients receiving anthracyclines
with or without trastuzumab, diastolic dysfunction
has been reported to precede systolic dysfunction and
CTRCD (47). We recommend diastolic assessment
should be undertaken in all baseline echocardio-
grams. Along with mitral E and A maximum velocity
(Vmax), E/A ratio, left atrial volumes, and TRV, TDI is
a key part of the assessment of diastolic function (48).
For more details on the grading of diastolic function,
the reader is directed to the current American Society
of Echocardiography/European Association of Car-




The term strain refers to an object’s fractional or per-
centage change from its original, unstressed dimen-
sion and reflects the deformation of a structure. When
applied to myocardium, this deformation or strain
directly describes the contraction/relaxation pattern.
At rest, an object that has an initial length (L0) can be
stretched or compressed to a new length (L). This
change in length is usually represented as a percent-
age, with a negative score indicating a shortening in
length. Should L equal L0, then strain remains zero.
Although LVEF is simple and intuitive, and sup-
ported by prognostic information, it has important
limitations including image quality dependence, geo-
metric assumptions, and insensitivity to early disease
(which is characterized by disturbances of longitudi-
nal function). Strain measurements, like LVEF mea-
surements, are dependent on endocardial border
tracing and therefore also rely on image quality.
The myocardial fiber orientation of the LV is com-
plex. The major limitation of the Doppler-based
approach is the angle dependency required during
image acquisition (50,51). This has been overcome by
speckle tracking echocardiography, which is based on
tracking the pattern of speckles generated by reflected
ultrasound signal. Different regions of myocardiumhave a unique speckle pattern that moves from one
frame to the next. Dedicated speckle tracking software
enables this movement to be quantified via several
parameters (such as longitudinal strain).
GLS is measured using a combination of the apical 2-
chamber (A2C), 3-chamber (A3C), and 4-chamber
(A4C) views (52). Longitudinal strain is the degree of
deformation from base to apex. During systole,
contraction in this plane leads to fiber shortening,
represented as a negative percentage value (i.e., the
more negative the value, the greater the deformation).
Although global circumferential and radial strain may
also indicate cardiotoxicity, there are less data to
support their clinical use (35), hence, the focus on GLS.
GLS has been shown to be superior to 2D LVEF with
regard to reproducibility in patients receiving trastu-
zumab (53) and has been suggested that it is more
reproducible with appropriate echocardiographic
training (54). It is therefore best practice that cardio-
oncology echocardiograms are performed on ma-
chines able to calculate GLS and which have 3D capa-
bilities. Small, but statistically significant, differences
between vendors exist; therefore the same acquisition
platform and analysis software should be used for se-
rial echocardiograms (55–57). The ability to perform
GLS and 3D measurements is beyond the current BSE
personal accreditation standards. It is therefore
important that individuals undertaking cardio-
oncology echocardiograms are suitably trained in
acquisition and analysis of these advanced echocar-
diography measures in a reproducible and consistent
manner. In addition, echo departments should estab-
lish and reassess their intra- and interobserver vari-
ability of 2D LVEF, 3D LVEF, and GLS.
How to perform GLS:
 GLS is calculated using the standard A3C, A4C, and
A2C views.
 Ensure an optimal ECG signal with minimal heart
rate variability is present across 3 cardiac cycles.
 Maintain a frame rate of 40 to 90 frames/s (33) at a
normal heart rate.
 Focus on the LV with appropriate adjustment of
width and depth.
 The technique used to select the appropriate ROI is
vendor-specific, and the reader is advised to con-
sult individual machine/software technical guide-
lines for further guidance. For General Electric
machines/software, adjust the overlay for the ROI.
In the A4C view, the ROI begins at the septal MV
annulus, progresses to the apex, and ends at the
lateral MV annulus. In the A2C view, the ROI starts
at the inferior MV annulus and extends through to
the apex and then to the anterior wall MV annulus.
TABLE 5 Key Echocardiographic Recommendations for Best Practice
Baseline assessment Full BSE minimum dataset echocardiogram, vital signs, and GLS/3D volumes (Table 1)
Follow-up assessment Targeted echocardiogram (Table 2)
If new symptoms, then full echocardiogram as per baseline assessment
Definition of cardiotoxicity LVEF: a decrease in LVEF by >10 absolute percentage points to a value <50%
Definition of probable cardiotoxicity by echocardiography LVEF: decrease in LVEF by >10 absolute percentage points to a value $50% with an
accompanying fall in GLS >15% (where GLS measurement available)
Definition of possible cardiotoxicity by echocardiography LVEF: a decrease in LVEF by <10 absolute percentage points to a value <50% or LV GLS:
when LVEF $50%, a relative percentage reduction in GLS by >15%
Poor endocardial definition Consider contrast echocardiography when endocardial definition precludes the accurate
assessment of LVEF (e.g., when a minimum of 2 contiguous LV segments from any
apical view are not seen on noncontrast images)
Depending on local expertise and availability, CMR imaging is an alternative modality in this context
CMR ¼ cardiac magnetic resonance; other abbreviations as in Tables 1 to 3.
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MV annulus, extends to the apex and finally to the
base of the septal wall, taking care not to extend
into the LV outflow tract.
 Two contours for speckle tracking are visible and
should be aligned with the relevant area of
interest:
B The endocardial border—the inner contour of
the myocardium
B The epicardial border—the outer border of the
myocardium (be careful to exclude the pericar-
dium, especially if automated analysis software
is used. Inclusion of pericardium will lead to an
underestimation of strain)
 Use optimal gain settings and breath-hold tech-
niques to clearly delineate the endocardial and
epicardial borders.
 During post-processing, the ROI should be aligned
as accurately as possible to reflect the 17-segment
LV model.
RIGHT HEART ASSESSMENT. Right heart (RH) struc-
ture and function has not traditionally been incor-
porated into the definition of CTRCD. However,
there is increasing evidence that RH abnormalities
may be prognostically significant (58,59), and
therefore assessment of the RH should be obtained
to include RV dimensions, RV S0, tricuspid annular
plane systolic excursion, and TRV. Abnormalities in
RH structure and function on serial echocardiogra-
phy should be discussed with a cardio-oncologist
and may require full assessment of the RH as per
the BSE practical guideline for RH assessment and
the BSE guideline on the assessment of pulmonary
hypertension (60,61).
ALTERNATIVE IMAGING MODALITIES
Although echocardiography remains the first-line
investigation for the detection of CTRCD, there is acomplementary role for other imaging modalities,
particularly in patients with inadequate echocardio-
graphic windows. Traditionally, multigated acquisi-
tion scans have been used in the assessment of LV
systolic function however, the associated radiation
exposure (a particular issue with the inevitable serial
scans) and limited structural information available
makes this an inferior investigation (62). CMR imag-
ing may be required in patients with poor echocar-
diographic windows or for tissue characterization
(e.g., cardiac masses and cancer treatment–related
myocarditis). Low inter- and intrareader variability
make it the optimal technique for detecting small
changes in LVEF in serial scans; however, its use is
still limited by its availability and cost (63,64). The
role of cardiac computed tomography is mainly in the
noninvasive evaluation of coronary artery disease,
but it can also be used to assess pericardial disease
and valvular heart disease, and in the imaging of
cardiac tumors (65,66).
RECOMMENDATION.
 Contrast 2D echocardiography should be consid-
ered when subendocardial definition precludes the
accurate assessment of LVEF, that is, when a
minimum of 2 contiguous LV segments from any
apical view are not seen on noncontrast images
(45).
 Depending on local expertise and availability, CMR
imaging is an alternative modality, particularly for
patients with poor echocardiographic windows.
 The same imaging modality should be used for
sequential scans.
CLINICAL RISK STRATIFICATION FOR CARDIOTOXICITY.
Risk stratification for cardiac dysfunction is recom-
mended before the commencement of potentially
cardiotoxic cancer treatment in all patients (14,16). A
clinical history and cardiovascular examination,
including blood pressure measurement, should be
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All patients should also have a baseline 12-lead ECG.
Although outside the scope of this document, bio-
markers (troponin and N-terminal pro–B-type natri-
uretic peptide [NT-proBNP]) may be considered in
high-risk patients to assist further risk stratification
(Table 3). Biomarkers may be able to detect subclini-
cal signs of LV systolic and diastolic dysfunction
before a decline in LVEF (67). Elevated baseline levels
should prompt more frequent monitoring because
there is some evidence that abnormal baseline high-
sensitivity troponin is associated with an increased
risk of developing complications with chemotherapy.
There is also an association between troponin release
after high-dose chemotherapy and subsequent car-
diac events (68–70). Persistent serial elevation of NT-
proBNP is associated with an increased risk of
developing overt heart failure, whereas a transient
rise is not (71). However, discussion of the utility and
prognostic value of biomarkers is beyond the scope of
this guideline, and the reader is directed to additional
references (27,72).
Defining the high-risk patient is challenging.
Although there is no validated unifying risk calculator
that is applicable to all cancer types and therapies
(73), recently published guidelines can help clinicians
with risk stratification (14). This highlights the need
for a tailored and individualized approach to the
assessment, treatment, and monitoring of cardio-
oncology patients.
REFERRAL TO A CARDIO-ONCOLOGY SERVICE
The cardio-oncology team is composed of specialized
health care professionals who work together to pro-
vide “consistent, continuous, coordinated and cost-
effective care during the cancer process” (74). This
highly specialized service is involved in patient care,
cardio-oncology research, and regional co-ordination
of services (75).
Echocardiography is pivotal to decision-making in
cardio-oncology, for example, when to consider
referral to a cardio-oncologist, when to initiate car-
dioprotective medications or heart failure therapy,
and when to hold or discontinue cardiotoxic cancer
therapy. Early detection of cardiac dysfunction, with
prompt initiation of cardioprotective medications,
increases the likelihood of LVEF recovery and may
reduce the cardiac event rate (76).
All patients with confirmed cardiotoxicity require
referral to a cardio-oncology service. Any patient with
pre-existing LV systolic dysfunction should bediscussed with the cardio-oncology team, ideally
before the commencement of cardiotoxic cancer
therapy (2). With increasing evidence that a signifi-
cant reduction in GLS accurately predicts subsequent
cardiotoxicity (35), referral to a cardio-oncology ser-
vice for expert review could be considered in patients
with >15% reduction in GLS despite a normal LVEF.
TREATMENT THRESHOLDS. Patients who develop
CTRCD (symptomatic or asymptomatic) benefit from
early introduction of angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers and/or beta-
blockers (77). Treatment thresholds vary in the pub-
lished reports (10,78,79). Treatment in asymptomatic
patients with declines in GLS, but not in LVEF, re-
mains controversial (13,80). Closer monitoring and/or
starting cardioprotective treatments are options to be
considered. There is no evidence at present to hold
cancer therapy based upon abnormal strain mea-
surements alone.
Recent studies have investigated the role of pre-
treatment with cardioprotective medications in can-
cer patients embarking on cardiotoxic therapy
(81–83). Results have been mixed, and such strategies
cannot currently be recommended as routine
practice.
CONCLUSIONS
Cardio-oncology is a relatively new and rapidly
developing subspecialty. Echocardiography is a key
imaging modality in the initial assessment and sub-
sequent monitoring of patients treated with
commonly used cardiotoxic drugs such as anthracy-
clines and trastuzumab. High-quality targeted LVEF
assessment incorporating 3D volumetric analysis and
strain measurement can be used to safely monitor
patients during and after treatment. Key echocar-
diographic recommendations are shown in Table 5.
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